Employees: 1,890
Size Chimin Health Management (603222.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $533M, the 3541st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.90 on 18 Nov 2026.
Performance Over six months the shares fell 30.9%, against -14.6% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 0.7% over the last twelve months (peer median +8.4%); the operating margin is -28.2% (peer median 11.0%).
Valuation It trades at 6.6× enterprise value to sales against a peer median of 5.2× (7th most expensive of 19).
Capital Return on invested capital runs 13.4 points below its cost of capital (9.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥639M | CN¥684M | CN¥764M | CN¥891M | CN¥833M |
| Revenue growth | — | -10% | -14% | +7% | — |
| Gross profit | CN¥244M | CN¥181M | CN¥245M | CN¥345M | CN¥360M |
| EBITDA | n/a | -CN¥32.8M | CN¥70.3M | CN¥152M | CN¥172M |
| Net income | -CN¥251M | -CN¥246M | -CN¥59.7M | -CN¥65.5M | CN¥34.5M |
| Free cash flow | -CN¥3.20M | -CN¥56.6M | -CN¥47.3M | -CN¥4.97M | CN¥19.2M |
| Capital expenditure | CN¥44.6M | CN¥46.2M | CN¥122M | CN¥149M | CN¥196M |
| Total debt | CN¥807M | CN¥728M | CN¥555M | CN¥509M | CN¥626M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603222.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.6% | -7.0% | 4th lowest of 20 |
| 6-month return | -30.9% | -14.6% | lowest of 19 |
| Distance from 52-week high | -44.2% | -38.7% | 6th lowest of 20 |
| Revenue growth (TTM) | +0.7% | +8.4% | 8th lowest of 19 |
| Operating margin | -28.2% | 11.0% | 4th lowest of 19 |
| EV / Sales | 6.6× | 5.2× | 7th most expensive of 19 |
| ROIC minus cost of capital | -13.4 pp | -1.5 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |